Mikabit is a prescription drug, available for use as Injection. Primarily, it is used for the treatment of Urinary Tract Infection. Mikabit also has some secondary and off-label uses. These are listed below.
The right dosage of Mikabit depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
While these are the most often observed Mikabit side effects, there are can be others also. These have been listed below. Usually, these side effects of Mikabit go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Mikabit is Severe for pregnant women and Unknown for women who are breastfeeding. Warnings related to Mikabit's effects on the liver, heart and kidney, if any, have been listed below.
Individuals suffering from medical conditions like Dehydration, Parkinson's Disease, Hearing Loss must refrain from the use of Mikabit since this can cause severe adverse effects. The section on Mikabit contraindications lists all such conditions.
Besides this, Mikabit may also have severe interaction with some medicines. Refer to the list below for further details.
In addition to these precautions, you may also note that Mikabit is safe while driving, and is is addictive in nature.
Mikabit is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
2 - 12 years (Child) |
|
Is the use of Mikabit safe for pregnant women?
Mikabit shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Mikabit safe during breastfeeding?
There is no research available on the side effects of Mikabit in breastfeeding women. Therefore, its impact is unknown.
What is the effect of Mikabit on the Kidneys?
Consumption of Mikabit can harm the kidneys. So it is important to take medical advice beforehand.
What is the effect of Mikabit on the Liver?
Very few cases of side effects of Mikabit on the liver have been reported.
What is the effect of Mikabit on the Heart?
Mikabit is rarely harmful for the heart.
Mikabit should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
If you are suffering from any of the following diseases, you should not take Mikabit unless your doctor advises you to do so -
Is this Mikabit habit forming or addictive?
Forming a habit of Mikabit has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Mikabit since it does not cause drowsiness.
Is it safe?
Mikabit is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Mikabit is not used to treat mental disorders.
Interaction between Food and Mikabit
Taking Mikabit with food does not harm your health.
Interaction between Alcohol and Mikabit
Due to lack of research, there is no information about the side effects of taking Mikabit with alcohol.
Do not self-administer Mikabit. It comes in the form of injection and given preferably 2 - 3 times in a day (Intravenously). Discontinuing the medicine in between may promote resistant bacteria which result in a relapse of the infection. You are recommended to complete the 7 - 10 days course even after getting symptomatic relief. In case you feel any discomfort such as hearing loss and nephrotoxicity while taking Mikabit please inform your doctor immediately.
No, Mikabit does not cause constipation in patients who are taking it. However, if you are experiencing constipation after taking this drug then inform your doctor and take precautionary methods such as eating fibrous foods to avoid constipation.
Mikabit is a brand name for amikacin. It is a prescription drug which belongs to the class of medication known as an aminoglycoside antibiotic. It is a broad spectrum antibiotic which is used for the treatment of bacterial infection such as bone, joint, skin, intra-abdominal, pneumonia, and respiratory tract infection. It is used for short-term treatment (7 - 10 days) of bacterial infection in different part of the body. It is also used for the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.
No, Mikabit cannot be taken with penicillin. Because penicillin inactivates the Mikabit by combining the beta-lactam ring of penicillin with an amino group of this drug to form amide which is biologically inactive. For this reason Mikabit should not be taken with penicillin. The chances of inactivation of this drug are higher in case of renal failure because in this case concentration of penicillin is higher in the kidney for a longer time as compared to the normal renal function.
Yes, Mikabit is nephrotoxic. Nephrotoxicity depends on dose and duration of therapy. Thus, nephrotoxicity is likely to occur if Mikabit taken a high dose for a long time or may occur if the drug is given to a patient that already suffer from kidney problem. Nephrotoxicity associated with this drug may reduce or minimize by taking some precaution before consuming this drug like monitor kidney functions regularly and do not take it in high doses. Avoid taking Mikabit with another nephrotoxic drug. If you notice any urine discoloration after taking this drug then inform your doctor immediately.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Arikayce (amikacin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 749
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 136-137